Good find koo. Thanks.

So another 4% dilution not counting warrants.

Positive aspects;

1. Don still able to find these one off investors willing to sink in significant $.
2. Possibly Eversana is helpful in keeping this pipeline going???
3. Staff probably getting paid.
4. Buys some time until we hear about FDA C type meeting results at which point Don can introduce shiek 2.0.
5. Don will be able to collect his approx $141,000 pay cheque for the last 3 months of hard work. Perhaps he could invest a buck in learning about how to do a webcast.  :)

It's a strange way to run a biotech with a very promising drug with FDA BTD for apabetalone, but as I see it, the requisit business skills do not exist in this company. Hey, if shiek 2.0 pops up and the covid and BoM2 trials get funded and are successful I think I'll be in the money within 3 to 5 years.

GLTA

Toinv